Company intelligence / Profile preview

Aegis Life, Inc.

San Diego, California, United Statesaegis.life ↗

Ownership: Private
Development stage: Phase 1

Overview

Aegis Life has advanced its lead COVID-19 vaccine candidate IAV-001 to Phase 1 clinical trials, while other programs for HIV, malaria, Lyme disease, and HPV remain in preclinical development. The company received a $4.45M investment from the Bill & Melinda Gates Foundation in March 2024 to continue development of DNA-encoded therapeutic antibodies against infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccinesDNA-encoded antibodiesNucleic acid-based vaccinesGene therapymRNA vaccinemRNA encoding antibody
Industry: Biotech

Drug pipeline

2 assets

Covigenix VAX-001

Phase 1/2

Indications: COVID-19

1 more asset in the full pipeline.

Request access →

Partnerships

Bill & Melinda Gates FoundationEntos Pharmaceuticals

Beyond the preview

Go deeper on Aegis Life, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aegis Life, Inc..

Explore the full profile